ATE165977T1 - Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie - Google Patents

Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie

Info

Publication number
ATE165977T1
ATE165977T1 AT93902861T AT93902861T ATE165977T1 AT E165977 T1 ATE165977 T1 AT E165977T1 AT 93902861 T AT93902861 T AT 93902861T AT 93902861 T AT93902861 T AT 93902861T AT E165977 T1 ATE165977 T1 AT E165977T1
Authority
AT
Austria
Prior art keywords
analgesia
enhancement
methods
opiate
producing
Prior art date
Application number
AT93902861T
Other languages
English (en)
Inventor
Alan Justice
Tejinder Singh
Kishor Chandra Gohil
Karen L Valentino
George P Miljanich
Original Assignee
Neurex Corp
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neurex Corp filed Critical Neurex Corp
Application granted granted Critical
Publication of ATE165977T1 publication Critical patent/ATE165977T1/de

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/43504—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from invertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/94—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving narcotics or drugs or pharmaceuticals, neurotransmitters or associated receptors
    • G01N33/9486—Analgesics, e.g. opiates, aspirine
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2500/00—Screening for compounds of potential therapeutic value

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Molecular Biology (AREA)
  • Engineering & Computer Science (AREA)
  • General Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Zoology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Genetics & Genomics (AREA)
  • Hematology (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Biomedical Technology (AREA)
  • Analytical Chemistry (AREA)
  • Pain & Pain Management (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Microbiology (AREA)
  • Emergency Medicine (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Cell Biology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Epidemiology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AT93902861T 1991-12-30 1992-12-30 Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie ATE165977T1 (de)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US81475991A 1991-12-30 1991-12-30

Publications (1)

Publication Number Publication Date
ATE165977T1 true ATE165977T1 (de) 1998-05-15

Family

ID=25215938

Family Applications (1)

Application Number Title Priority Date Filing Date
AT93902861T ATE165977T1 (de) 1991-12-30 1992-12-30 Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie

Country Status (9)

Country Link
US (3) US5587454A (de)
EP (1) EP0625162B1 (de)
AT (1) ATE165977T1 (de)
AU (1) AU689438B2 (de)
CA (1) CA2151741C (de)
DE (1) DE69225499T2 (de)
HK (1) HK1013832A1 (de)
SG (1) SG50624A1 (de)
WO (1) WO1993013128A1 (de)

Families Citing this family (80)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5824645A (en) * 1991-12-30 1998-10-20 Neurex Corporation Method of treating inflammation
US5591821A (en) * 1993-07-16 1997-01-07 The University Of Utah Omega-conotoxin peptides
US5739276A (en) * 1994-10-07 1998-04-14 University Of Utah Research Foundation Conotoxin peptides
US5623051A (en) * 1994-11-10 1997-04-22 University Of Washington Methods and compositions for screening for presynaptic calcium channel blockers
US5670622A (en) * 1996-02-15 1997-09-23 University Of Utah Research Foundation Conotoxin peptide PIIIA
US6054429A (en) * 1996-03-08 2000-04-25 Elan Pharmaceuticals, Inc. Epidural method of producing analgesia
DK0835126T3 (da) * 1995-06-27 2003-07-14 Elan Pharm Inc Sammensætninger og formuleringer til fremstilling af analgesimidler og til hamning af fremadskridende neuropatiske amertelidelser
US5795864A (en) * 1995-06-27 1998-08-18 Neurex Corporation Stable omega conopetide formulations
US5931809A (en) 1995-07-14 1999-08-03 Depotech Corporation Epidural administration of therapeutic compounds with sustained rate of release
AU6454096A (en) * 1995-07-26 1997-02-26 Warner-Lambert Company Use of neuronal calcium channel blockers for the manufacture of a medicament for the treatment of psychoses, schizophrenia and ***e or amphetamine addiction
US5965534A (en) * 1995-11-22 1999-10-12 Alcon Laboratories, Inc. Use of ω-conotoxin analogs for treating retinal and optic nerve head damage
US5776896A (en) * 1996-01-03 1998-07-07 Zeneca Limited Analgesic peptides from venom of grammostola spatulata and use thereof
US6060271A (en) * 1996-02-09 2000-05-09 Cornell Research Foundation, Inc. CDNA fragments corresponding to voltage gated sodium channel genes expressed in peripheral nerve
US5672682A (en) * 1996-03-18 1997-09-30 University Of Utah Research Foundation Conotoxin peptide PVIIA
US6489119B1 (en) * 1996-03-29 2002-12-03 Elan Pharmaceuticals, Inc. Analgesic screening method and composition
AU7080698A (en) 1997-04-25 1998-11-24 Ajinomoto Co., Inc. Novel dihydropyridine derivative
US5844077A (en) 1997-04-28 1998-12-01 Cytotherapeutics, Inc. Use of conantokins for producing analgesia or for neuroprotection
AU9021298A (en) * 1997-08-15 1999-03-08 Carolyn Ann Fairbanks Agmatine as a treatment for neuropathic pain
CA2224066A1 (en) * 1997-10-24 1999-04-24 Universite D'ottawa/ University Of Ottawa Peptides as analgesics
CA2315910A1 (en) 1997-12-22 1999-07-01 Ajinomoto Co., Inc. Novel dihydropyridine derivative
EP1071707A4 (de) * 1998-04-16 2004-12-22 Univ Queensland Neue omegaconotoxin peptide
AUPP627498A0 (en) * 1998-10-02 1998-10-22 University Of Queensland, The Novel peptides - i
US6369193B1 (en) * 1998-10-20 2002-04-09 University Of Utah Research Foundation Contulakin-G, analogs thereof and uses therefor
US6268473B1 (en) 1999-01-22 2001-07-31 University Of Utah Research Foundation α-conotoxin peptides
US6855805B2 (en) 1999-01-22 2005-02-15 University Of Utah Research Foundation α-conotoxin peptides
US7378400B2 (en) * 1999-02-01 2008-05-27 University Of Virginia Patent Foundation Method to reduce an inflammatory response from arthritis
EP1191021A4 (de) 1999-06-23 2002-08-07 Ajinomoto Kk Dihydropyridin-derivat
EP1191022A4 (de) 1999-06-23 2002-09-18 Ajinomoto Kk Neuartige dihydropyridin-derivate
EP1193259A4 (de) 1999-06-23 2003-01-29 Ajinomoto Kk Dihydropyrimidinderivate
NZ517250A (en) 1999-08-10 2004-12-24 Uab Research Foundation Method of treating traumatic brain and spinal cord injuries and other neurogenic conditions using non-steroidal anti-inflammatory drugs (NSAID) and naturally occurring conotoxins
JP2003533178A (ja) * 1999-12-30 2003-11-11 ユニバーシティ・オブ・ユタ・リサーチ・ファウンデーション Ｏ−スーパーファミリー・コノトキシンペプチド
CA2416287A1 (en) * 2000-07-21 2002-01-31 University Of Utah Research Foundation Omega-conopeptides
US20030119731A1 (en) * 2000-07-21 2003-06-26 University Of Utah Research Foundation Omega-conopeptides
CA2441889A1 (en) * 2001-03-23 2002-10-03 Albert Einstein College Of Medicine Of Yeshiva University Methods for increasing analgesic potency and attenuating adverse excitatory effects of bimodally-acting opioid agonists by inhibiting gm1-ganglioside
CN1269482C (zh) * 2001-05-18 2006-08-16 威克斯医药有限公司 钠离子通道阻断剂和阿片类镇痛剂在制备用于对哺乳动物进行协同镇痛的药物中的应用
JP4514452B2 (ja) * 2001-10-01 2010-07-28 ユニバーシティ オブ バージニア パテント ファウンデーション Ａ２ａアゴニスト活性を有する２−プロピルアデノシン・アナログおよびその組成物
ATE381336T1 (de) * 2002-04-10 2008-01-15 Univ Virginia Verwendung von a2a adenosin rezeptor agonisten und anti-pathogene mittel enthaltenden kombinationen zur behandlung von entzündungskrankheiten
EP1572725B1 (de) * 2002-12-02 2012-02-29 Xenome Ltd Chi-conotoxinpeptide mit einer n-terminalen pyroglutaminsäure
WO2004050688A1 (en) * 2002-12-02 2004-06-17 Xenome Ltd NOVEL χ-CONOTOXIN PEPTIDES (-II)
US7772188B2 (en) 2003-01-28 2010-08-10 Ironwood Pharmaceuticals, Inc. Methods and compositions for the treatment of gastrointestinal disorders
DE602004007105T2 (de) 2003-01-28 2008-02-28 Microbia Inc., Cambridge Zusammensetzung zur behandlung von gastrointestinalen störungen
US7365050B2 (en) * 2003-08-08 2008-04-29 The Regents Of The University Of California Methods for modulating a drug-related effect or behavior
CA2540895C (en) 2003-10-02 2016-08-02 Elan Pharmaceuticals, Inc. Combinations of ziconotide and opioids for reducing pain
CN101068825B (zh) * 2004-08-02 2013-05-08 弗吉尼亚大学专利基金会 具有a2a激动剂活性的具有修饰的5＇-核糖基团的2-丙炔基腺苷类似物
WO2006028618A1 (en) * 2004-08-02 2006-03-16 University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs with modified 5'-ribose groups having a2a agonist activity
US7442687B2 (en) * 2004-08-02 2008-10-28 The University Of Virginia Patent Foundation 2-polycyclic propynyl adenosine analogs having A2A agonist activity
CA2577408C (en) * 2004-09-10 2013-07-09 Elena Barbanti Use of (halobenzyloxy) benzylamino-propanamides for the manufacture of medicaments active as sodium and/or calcium channel selective modulators
US8022177B2 (en) * 2005-09-30 2011-09-20 The Board Of Trustees Of The University Of Illinois Peptides and calcium regulation in mammalian cells
US8299211B2 (en) * 2005-09-30 2012-10-30 The Board Of Trustees Of The University Of Illinois Peptides and regulation of calcium channels
PT1963280E (pt) * 2005-12-22 2016-02-02 Newron Pharm Spa Derivados de 2-feniletilamino como cálcio e/ou moduladores do canal de sódio
US8178509B2 (en) * 2006-02-10 2012-05-15 University Of Virginia Patent Foundation Method to treat sickle cell disease
US8188048B2 (en) 2006-06-23 2012-05-29 Xenome Limited Combination therapy
AU2008261102B2 (en) 2007-06-04 2013-11-28 Bausch Health Ireland Limited Agonists of guanylate cyclase useful for the treatment of gastrointestinal disorders, inflammation, cancer and other disorders
US8969514B2 (en) 2007-06-04 2015-03-03 Synergy Pharmaceuticals, Inc. Agonists of guanylate cyclase useful for the treatment of hypercholesterolemia, atherosclerosis, coronary heart disease, gallstone, obesity and other cardiovascular diseases
HUE038113T2 (hu) 2007-06-15 2018-09-28 Newron Pharm Spa Helyettesített 2-[2-(fenil)-etilamino]-alkánamid-származékok és alkalmazásuk nátrium- és/vagy kalciumcsatorna-modulátorokként
US8058259B2 (en) 2007-12-20 2011-11-15 University Of Virginia Patent Foundation Substituted 4-{3-[6-amino-9-(3,4-dihydroxy-tetrahydro-furan-2-yl)-9H-purin-2-yl]-prop-2-ynyl}-piperidine-1-carboxylic acid esters as A2AR agonists
EP2328910B1 (de) 2008-06-04 2014-08-06 Synergy Pharmaceuticals Inc. Für die behandlung von gastrointestinalen erkrankungen, entzündungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
EP3241839B1 (de) 2008-07-16 2019-09-04 Bausch Health Ireland Limited Zur behandlung von erkrankungen des magen-darm-trakts, entzündlichen erkrankungen, krebs und anderen erkrankungen geeignete agonisten von guanylatcyclase
CA2745694C (en) 2008-12-03 2018-03-27 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase c agonists and methods of use
KR20200111230A (ko) 2008-12-31 2020-09-28 알데릭스, 인코포레이티드 체액 저류 또는 염 과부하와 연관된 장애 및 위장관 장애의 치료 시에 ｎｈｅ-매개된 역수송을 억제하는 화합물 및 방법
WO2018129556A1 (en) 2017-01-09 2018-07-12 Ardelyx, Inc. Compounds and methods for inhibiting nhe-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
US9616097B2 (en) 2010-09-15 2017-04-11 Synergy Pharmaceuticals, Inc. Formulations of guanylate cyclase C agonists and methods of use
MX357121B (es) 2011-03-01 2018-06-27 Synergy Pharmaceuticals Inc Star Proceso de preparacion de agonistas c de guanilato ciclasa.
CN103781759B (zh) 2011-06-27 2016-01-13 纽朗制药有限公司 氟化的芳基烷基氨基甲酰胺衍生物
US10376481B2 (en) 2012-08-21 2019-08-13 Ardelyx, Inc. Compounds and methods for inhibiting NHE-mediated antiport in the treatment of disorders associated with fluid retention or salt overload and gastrointestinal tract disorders
EP2887964B1 (de) 2012-08-21 2019-07-03 Ardelyx, Inc. Verbindungen und verfahren zur hemmung von nhe-vermitteltem antiport bei der behandlung von erkrankungen im zusammenhang mit flüssigkeitsretention oder salzüberlastung und erkrankungen des gastrointestinaltraktes
AU2014235209B2 (en) 2013-03-15 2018-06-14 Bausch Health Ireland Limited Guanylate cyclase receptor agonists combined with other drugs
WO2014151206A1 (en) 2013-03-15 2014-09-25 Synergy Pharmaceuticals Inc. Agonists of guanylate cyclase and their uses
PL2983667T3 (pl) 2013-04-12 2019-10-31 Ardelyx Inc Związki wiążące nhe3 oraz sposoby inhibicji transportu fosforanów
BR112015030326A2 (pt) 2013-06-05 2017-08-29 Synergy Pharmaceuticals Inc Agonistas ultrapuros de guanilato ciclase c, método de fabricar e usar os mesmos
US11602513B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
UY37341A (es) 2016-07-22 2017-11-30 Flamel Ireland Ltd Formulaciones de gamma-hidroxibutirato de liberación modificada con farmacocinética mejorada
US11504347B1 (en) 2016-07-22 2022-11-22 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11602512B1 (en) 2016-07-22 2023-03-14 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11986451B1 (en) 2016-07-22 2024-05-21 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
AU2018205400B2 (en) 2017-01-09 2022-07-14 Ardelyx, Inc. Compounds useful for treating gastrointestinal tract disorders
JP2020505333A (ja) 2017-01-09 2020-02-20 アルデリックス， インコーポレイテッド Ｎｈｅ媒介性アンチポートの阻害薬
JP2022522270A (ja) 2019-03-01 2022-04-15 フラメル アイルランド リミテッド 食事摂取状態における改善された薬物動態を有するガンマ－ヒドロキシ酪酸塩組成物
US11779557B1 (en) 2022-02-07 2023-10-10 Flamel Ireland Limited Modified release gamma-hydroxybutyrate formulations having improved pharmacokinetics
US11583510B1 (en) 2022-02-07 2023-02-21 Flamel Ireland Limited Methods of administering gamma hydroxybutyrate formulations after a high-fat meal

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5196204A (en) * 1986-10-20 1993-03-23 University Of Utah Research Foundation Spider toxins and methods for their use as blockers of calcium channels and amino acid receptor function
US5064657A (en) * 1986-10-20 1991-11-12 University Of Utah Spider toxins and methods for their use as blockers of amino acid receptor function
US5871472A (en) * 1987-11-17 1999-02-16 Brown University Research Foundation Planting devices for the focal release of neuroinhibitory compounds
DE3926287A1 (de) * 1989-08-09 1991-02-21 Bernhard Clasbrummel Medizinische anwendung von omega-conotoxin gvia oder omega-conotoxin gvia-analoga zur sympathikolyse
US5051403A (en) * 1989-11-22 1991-09-24 Neurex Corporation Method of treating ischemia-related neuronal damage
US5189020A (en) * 1989-11-22 1993-02-23 Neurex Corporation Method of reducing neuronal damage using omega conotoxin peptides
US5221254A (en) * 1991-04-02 1993-06-22 Alza Corporation Method for reducing sensation in iontophoretic drug delivery
US5231011A (en) * 1991-04-18 1993-07-27 University Of Utah Segregated folding determinants for small disulfide-rich peptides

Also Published As

Publication number Publication date
SG50624A1 (en) 1998-07-20
CA2151741A1 (en) 1993-07-08
EP0625162B1 (de) 1998-05-13
CA2151741C (en) 2001-12-11
WO1993013128A1 (en) 1993-07-08
US5587454A (en) 1996-12-24
AU689438B2 (en) 1998-04-02
US5364842A (en) 1994-11-15
US5859186A (en) 1999-01-12
HK1013832A1 (en) 1999-09-10
AU3428093A (en) 1993-07-28
DE69225499T2 (de) 1999-02-04
DE69225499D1 (de) 1998-06-18
EP0625162A1 (de) 1994-11-23

Similar Documents

Publication Publication Date Title
ATE165977T1 (de) Methoden zur erzeugung von analgesie und zur verstärkung von opiat-analgesie
ATE181320T1 (de) Verfahren zur herstellung von mischungen von n- acylierten aminosaeuren
DE69434703D1 (de) Verfahren zur Erzeugung von DSA-Unterschriften mit preisgünstigen tragbaren Einheiten
DE68928934D1 (de) Verfahren zur herstellung von menschlicher dnase
DE59000200D1 (de) Verfahren zur gewinnung von erdgas.
ATE326476T1 (de) Verfahren zur herstellung von phosphorothioat- oligomeren
DE59611165D1 (de) Verfahren zur Herstellung von Ausweiskarten
DE69111440D1 (de) Methoden und zusammensetzungen zur impfung gegen hiv.
DE69018920D1 (de) Verwendung von dns-fragmenten, die ein signalpeptid kodieren zur sekretion von reifen proteinen in rekombinanten hefen, expressions-kassetten, transformierte hefen und verfahren zur herstellung dieser proteine.
DE69432704D1 (de) Verfahren zur Herstellung von humanen Relaxin
ATE265529T1 (de) Bmp-10 zusammensetzungen
DE69813212D1 (de) Verfahren zur erzeugung von proteinhydrolysaten
DE3583896D1 (de) Verfahren und vorrichtung zur herstellung von weissen zementklinkern.
DE3751179D1 (de) Peptide, die die Bindung des Von-Willebrand-Faktors inhibieren.
ATE184917T1 (de) Rekombinante methode und wirt zur herstellung von xylitol
ATE164065T1 (de) Neues verfahren zur behandlung von depression
DE69407272D1 (de) Verfahren zum reinigen von 20 cs)-camptothecin
ATE204291T1 (de) Verfahren zur herstellung von peptiden und n- carbamoyl-geschützten peptiden
ATE71109T1 (de) Verfahren zur spaltung von peptiden und proteinen an der methionyl-bindung.
ATE309353T1 (de) Verfahren zur herstellung von rekombinanten peptiden
DE3853156D1 (de) Polyestergewebe zur herstellung von elektrophoresegelen und elektrophoresegel.
DE69734464D1 (de) Verfahren zur expression und herstellung von rekombinantem, menschlichem beta-cis-interferon
ATE80594T1 (de) Verfahren zur herstellung von boriden der seltenen erden.
ATE319738T1 (de) Verfahren zur herstellung eines sets von kombinatorischen polypeptidantigenen
DE3870558D1 (de) Verfahren zur erzeugung und verteilung von geheimschluesseln.